Definium Therapeutics annual stock-based compensation
2020
2021
2022
2023
2024
2025
Definium Therapeutics Stock-Based Compensation Growth & History (DFTX)
Definium Therapeutics's stock-based compensation was $20.1M for fiscal 2025.
View full Definium Therapeutics company overviewDefinium Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $20.1M | $3.2M | +18.82% |
| 2024 | 2024-12-31 | $16.9M | $1.7M | +11.39% |
| 2023 | 2023-12-31 | $15.2M | $1.5M | +10.77% |
| 2022 | 2022-12-31 | $13.7M | −$29.0M | −67.91% |
| 2021 | 2021-12-31 | $42.7M | $35.3M | +476.78% |
| 2020 | 2020-12-31 | $7.4M | — | — |
Definium Therapeutics quarterly stock-based compensation
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $9.6M | $4.4M | +83.50% |
| Q1 2026 | 2026-03-31 | $7.1M | $3.7M | +108.17% |
| Q4 2025 | 2025-12-31 | $5.6M | $1.6M | +41.69% |
| Q3 2025 | 2025-09-30 | $5.8M | $2.0M | +51.42% |
| Q2 2025 | 2025-06-30 | $5.3M | −$177,000 | −3.26% |
| Q1 2025 | 2025-03-31 | $3.4M | −$263,000 | −7.13% |
| Q4 2024 | 2024-12-31 | $4.0M | $588,000 | +17.47% |
| Q3 2024 | 2024-09-30 | $3.8M | −$385,000 | −9.11% |
| Q2 2024 | 2024-06-30 | $5.4M | $1.6M | +41.33% |
| Q1 2024 | 2024-03-31 | $3.7M | −$61,000 | −1.63% |
| Q4 2023 | 2023-12-31 | $3.4M | $2.0M | +144.55% |
| Q3 2023 | 2023-09-30 | $4.2M | −$60,000 | −1.40% |
| Q2 2023 | 2023-06-30 | $3.8M | −$411,000 | −9.66% |
| Q1 2023 | 2023-03-31 | $3.8M | −$42,000 | −1.11% |
| Q4 2022 | 2022-12-31 | $1.4M | −$3.0M | −68.32% |
| Q3 2022 | 2022-09-30 | $4.3M | $181,000 | +4.41% |
| Q2 2022 | 2022-06-30 | $4.3M | −$28.7M | −87.11% |
| Q1 2022 | 2022-03-31 | $3.8M | $2.5M | +196.48% |
| Q4 2021 | 2021-12-31 | $4.3M | — | — |
| Q3 2021 | 2021-09-30 | $4.1M | — | — |
| Q2 2021 | 2021-06-30 | $33.0M | — | — |
| Q1 2021 | 2021-03-31 | $1.3M | — | — |
Definium Therapeutics stock-based compensation trends
Over the last five fiscal years, Definium Therapeutics's stock-based compensation increased from $7.4M to $20.1M, a change of $12.7M. The latest reported quarter, Q2 2026, shows $9.6M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Definium Therapeutics source filings ↗